Antoni Benito

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7073794/publications.pdf

Version: 2024-02-01

65 papers	1,164 citations	411340 20 h-index	488211 31 g-index
65 all docs	65 docs citations	65 times ranked	992 citing authors

#	Article	IF	Citations
1	All-in-one biofabrication and loading of recombinant vaults in human cells. Biofabrication, 2022, 14, 025018.	3.7	6
2	Strengths and Challenges of Secretory Ribonucleases as AntiTumor Agents. Pharmaceutics, 2021, 13, 82.	2.0	7
3	The Selectivity for Tumor Cells of Nuclear-Directed Cytotoxic RNases Is Mediated by the Nuclear/Cytoplasmic Distribution of p27KIP1. Molecules, 2021, 26, 1319.	1.7	1
4	A Nuclear-Directed Ribonuclease Variant Targets Cancer Stem Cells and Inhibits Migration and Invasion of Breast Cancer Cells. Cancers, 2021, 13, 4350.	1.7	2
5	A family of manganese complexes containing heterocyclic-based ligands with cytotoxic properties. Journal of Inorganic Biochemistry, 2018, 182, 124-132.	1.5	8
6	Construction of Highly Stable Cytotoxic Nuclear-Directed Ribonucleases. Molecules, 2018, 23, 3273.	1.7	2
7	Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance. OncoTargets and Therapy, 2018, Volume 11, 221-237.	1.0	11
8	Structural Insights into Subunits Assembly and the Oxyester Splicing Mechanism of Neq pol Split Intein. Cell Chemical Biology, 2018, 25, 871-879.e2.	2.5	5
9	Apoptin, A Versatile Protein with Selective Antitumor Activity. Current Medicinal Chemistry, 2018, 25, 3540-3559.	1.2	9
10	Insights into the mechanism of Apoptin's exquisitely selective anti-tumor action from atomic level characterization of its conformation and dynamics. Archives of Biochemistry and Biophysics, 2017, 614, 53-64.	1.4	3
11	A truncated apoptin protein variant selectively kills cancer cells. Investigational New Drugs, 2017, 35, 260-268.	1.2	6
12	Activating transcription factor 3 is crucial for antitumor activity and to strengthen the antiviral properties of Onconase. Oncotarget, 2017, 8, 11692-11707.	0.8	20
13	A nuclear-directed human pancreatic ribonuclease (PE5) targets the metabolic phenotype of cancer cells. Oncotarget, 2016, 7, 18309-18324.	0.8	15
14	1H, 13C and 15N resonance assignments of the Onconase FL-G zymogen. Biomolecular NMR Assignments, 2013, 7, 13-15.	0.4	1
15	Towards Tricking a Pathogenâ€™s Protease into Fighting Infection: The 3D Structure of a Stable Circularly Permuted Onconase Variant Cleavedby HIV-1 Protease. PLoS ONE, 2013, 8, e54568.	1.1	7
16	Mini-Review: Nucleus-Targeted Ribonucleases As Antitumor Drugs. Current Medicinal Chemistry, 2013, 20, 1225-1231.	1.2	19
17	A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines. Investigational New Drugs, 2012, 30, 880-888.	1.2	19
18	Generation of New Cytotoxic Human Ribonuclease Variants Directed to the Nucleus. Molecular Pharmaceutics, 2012, 9, 2894-2902.	2.3	11

#	Article	IF	Citations
19	Interactions Crucial for Three-Dimensional Domain Swapping in the HP-RNase Variant PM8. Biophysical Journal, 2011, 101, 459-467.	0.2	3
20	Antitumor Ribonucleases. Nucleic Acids and Molecular Biology, 2011, , 55-88.	0.2	5
21	The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity. Investigational New Drugs, 2011, 29, 811-817.	1.2	13
22	A human ribonuclease induces apoptosis associated with p21WAF1/CIP1induction and JNK inactivation. BMC Cancer, 2011, 11, 9.	1.1	40
23	Mapping the stability clusters in bovine pancreatic ribonuclease A. Biopolymers, 2009, 91, 1038-1047.	1.2	5
24	Ribonucleases directed to the nucleus as a novel proapoptotic anticancer strategy. New Biotechnology, 2009, 25, S8-S9.	2.4	0
25	Bactericidal Activity Engineered on Human Pancreatic Ribonuclease and Onconase. Molecular Pharmaceutics, 2009, 6, 531-542.	2.3	6
26	Destabilizing Mutations Alter the Hydrogen Exchange Mechanism in Ribonuclease A. Biophysical Journal, 2008, 94, 2297-2305.	0.2	11
27	Human pancreatic ribonuclease presents higher endonucleolytic activity than ribonuclease A. Archives of Biochemistry and Biophysics, 2008, 471, 191-197.	1.4	7
28	Contribution of the C30/C75 disulfide bond to the biological properties of onconase. Biological Chemistry, 2008, 389, 1127-1136.	1.2	7
29	The Structural Determinants that Lead to the Formation of Particular Oligomeric Structures in the Pancreatic-Type Ribonuclease Family. Current Protein and Peptide Science, 2008, 9, 370-393.	0.7	16
30	Intracellular Routing of Cytotoxic Pancreatic-Type Ribonucleases. Current Pharmaceutical Biotechnology, 2008, 9, 169-179.	0.9	18
31	Contribution of the C30/C75 disulfide bond to the biological properties of onconase. Biological Chemistry, 2008, .	1.2	0
32	Intracellular pathway of Onconase that enables its delivery to the cytosol. Journal of Cell Science, 2007, 120, 1405-1411.	1.2	55
33	A Cytotoxic Ribonuclease Variant with a Discontinuous Nuclear Localization Signal Constituted by Basic Residues Scattered Over Three Areas of the Molecule. Journal of Molecular Biology, 2006, 360, 548-557.	2.0	22
34	Characterization of the dimerization process of a domain-swapped dimeric variant of human pancreatic ribonuclease. FEBS Journal, 2006, 273, 1166-1176.	2.2	9
35	Pressure as a tool to study protein-unfolding/refolding processes: The case of ribonuclease A. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2006, 1764, 461-469.	1.1	25
36	The contribution of the residues from the main hydrophobic core of ribonuclease A to its pressure-folding transition state. Protein Science, 2006, 15, 1000-1009.	3.1	17

#	Article	IF	Citations
37	Pressure- and temperature-induced unfolding studies: thermodynamics of core hydrophobicity and packing of ribonuclease A. Biological Chemistry, 2006, 387, 285-296.	1.2	16
38	On the track of antitumour ribonucleases. Molecular BioSystems, 2005, 1, 294.	2.9	69
39	Quantitative analysis, using MALDI-TOF mass spectrometry, of the N-terminal hydrolysis and cyclization reactions of the activation process of onconase. FEBS Journal, 2004, 271, 1163-1171.	0.2	20
40	A Nuclear Localization Sequence Endows Human Pancreatic Ribonuclease with Cytotoxic Activityâ€. Biochemistry, 2004, 43, 2167-2177.	1.2	55
41	Stabilization of human pancreatic ribonuclease through mutation at its N-terminal edge. Protein Engineering, Design and Selection, 2002, 15, 887-893.	1.0	11
42	Purification of Engineered Human Pancreatic Ribonuclease. Methods in Enzymology, 2001, 341, 221-234.	0.4	27
43	The Structure of an Engineered Domain-Swapped Ribonuclease Dimer and Its Implications for the Evolution of Proteins toward Oligomerization. Structure, 2001, 9, 967-976.	1.6	45
44	Three-dimensional structure of a human pancreatic ribonuclease variant, a step forward in the design of cytotoxic ribonucleases. Journal of Molecular Biology, 2000, 303, 49-59.	2.0	30
45	Active concentration measurements of recombinant biomolecules using biosensor technology. Journal of Molecular Recognition, 1999, 12, 300-309.	1.1	35
46	Production of Engineered Human Pancreatic Ribonucleases, Solving Expression and Purification Problems, and Enhancing Thermostability. Protein Expression and Purification, 1999, 17, 169-181.	0.6	22
47	Biosensor characterization of antigenic site A of foot-and-mouth disease virus presented in different vector systems. FEMS Immunology and Medical Microbiology, 1998, 21, 101-115.	2.7	12
48	A cell adhesion peptide from foot-and-mouth disease virus can direct cell targeted delivery of a functional enzyme. , 1998, 59, 294-301.		7
49	The expression of recombinant genes from bacteriophage lambda strong promoters triggers the SOS response inEscherichia coli. , 1998, 60, 551-559.		31
50	Display-Induced Antigenic Variation in Recombinant Peptides. Biochemical and Biophysical Research Communications, 1998, 248, 773-777.	1.0	7
51	Conformational flexibility in a highly mobile protein loop of foot-and-mouth disease virus: distinct structural requirements for integrin and antibody binding 1 1Edited by J. Karn. Journal of Molecular Biology, 1998, 283, 331-338.	2.0	20
52	The position of the heterologous domain can influence the solubility and proteolysis of Î²-galactosidase fusion proteins in E. coli. Journal of Biotechnology, 1996, 48, 191-200.	1.9	63
53	Converging antigenic structure of a recombinant viral peptide displayed on different frameworks of carrier proteins. FEBS Letters, 1996, 397, 169-172.	1.3	4
54	A recombinant, arginine-glycine-aspartic acid (RGD) motif from foot-and-mouth disease virus binds mammalian cells through vitronectin and, to a lower extent, fibronectin receptors. Gene, 1996, 180, 101-106.	1.0	22

#	Article	IF	Citations
55	Î²-Galactosidase Enzymatic Activity as a Molecular Probe to Detect Specific Antibodies. Journal of Biological Chemistry, 1996, 271, 21251-21256.	1.6	49
56	Peptide insertions in ?-galactosidase activating interface can improve binding in TPEG-Sepharose affinity chromatography. Biotechnology Letters, 1995, 9, 767-770.	0.5	3
57	Improved Mimicry of a Foot-and-Mouth Disease Virus Antigenic Site by a Viral Peptide Displayed on Î²-Galactosidase Surface. Bio/technology, 1995, 13, 801-804.	1.9	52
58	Ammonium-Mediated Reduction of Plasmid Copy Number and Recombinant Gene Expression in Escherichia coli. Biotechnology Progress, 1994, 10, 648-651.	1.3	16
59	Uses of Î²-galactosidase tag in on-line monitoring production of fusion proteins and gene expression in Escherichia coli. Enzyme and Microbial Technology, 1993, 15, 66-71.	1.6	24
60	Enhanced production of pL-controlled recombinant proteins and plasmid stability in Escherichia coli RecA+ strains. Journal of Biotechnology, 1993, 29, 299-306.	1.9	33
61	Fine regulation of cI857-controlled gene expression in continuous culture of recombinant Escherichia coli by temperature. Applied and Environmental Microbiology, 1993, 59, 3485-3487.	1.4	69
62	Simultaneous on line monitoring of intracellular Î²-galactosidase activity and biomass using flow injection analysis inEscherichia coli batch fermentations. Biotechnology Letters, 1992, 6, 213-218.	0.5	8
63	A model for continuous production of thermally induced recombinant proteins. Biotechnology Letters, 1991, 13, 249-254.	1.1	1
64	Approaches to Endow Ribonucleases with Antitumor Activity: Lessons Learned from the Native Cytotoxic Ribonucleases. , 0, , .		1
65	Biosensor characterization of antigenic site A of foot-and-mouth disease virus presented in different vector systems. , 0, .		1